310 related articles for article (PubMed ID: 24623585)
21. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer.
Lefebvre S; Antoine M; Uzan S; McMaster M; Dausset J; Carosella ED; Paul P
J Pathol; 2002 Mar; 196(3):266-74. PubMed ID: 11857488
[TBL] [Abstract][Full Text] [Related]
22. Soluble HLA-G inhibits human dendritic cell-triggered allogeneic T-cell proliferation without altering dendritic differentiation and maturation processes.
Le Friec G; Laupèze B; Fardel O; Sebti Y; Pangault C; Guilloux V; Beauplet A; Fauchet R; Amiot L
Hum Immunol; 2003 Aug; 64(8):752-61. PubMed ID: 12878353
[TBL] [Abstract][Full Text] [Related]
23. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
[TBL] [Abstract][Full Text] [Related]
24. HLA-G1 and HLA-G5 isoforms have an additive effect on NK cytolysis.
Zhang WQ; Xu DP; Liu D; Li YY; Ruan YY; Lin A; Yan WH
Hum Immunol; 2014 Feb; 75(2):182-9. PubMed ID: 24269702
[TBL] [Abstract][Full Text] [Related]
25. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.
Wong R; Lau R; Chang J; Kuus-Reichel T; Brichard V; Bruck C; Weber J
Clin Cancer Res; 2004 Aug; 10(15):5004-13. PubMed ID: 15297401
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity.
Mao Y; Sarhan D; Steven A; Seliger B; Kiessling R; Lundqvist A
Clin Cancer Res; 2014 Aug; 20(15):4096-106. PubMed ID: 24907113
[TBL] [Abstract][Full Text] [Related]
27. HLA-G1 and HLA-G5 active dimers are present in malignant cells and effusions: the influence of the tumor microenvironment.
Zilberman S; Schenowitz C; Agaugué S; Benoît F; Riteau B; Rouzier R; Carosella ED; Rouas-Freiss N; Menier C
Eur J Immunol; 2012 Jun; 42(6):1599-608. PubMed ID: 22678912
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells.
Poggi A; Zocchi MR
Arch Immunol Ther Exp (Warsz); 2006; 54(5):323-33. PubMed ID: 17031467
[TBL] [Abstract][Full Text] [Related]
29. Mature B cells are critical to T-cell-mediated tumor immunity induced by an agonist anti-GITR monoclonal antibody.
Zhou P; Qiu J; L'Italien L; Gu D; Hodges D; Chao CC; Schebye XM
J Immunother; 2010 Oct; 33(8):789-97. PubMed ID: 20842058
[TBL] [Abstract][Full Text] [Related]
30. Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma.
del Campo AB; Kyte JA; Carretero J; Zinchencko S; Méndez R; González-Aseguinolaza G; Ruiz-Cabello F; Aamdal S; Gaudernack G; Garrido F; Aptsiauri N
Int J Cancer; 2014 Jan; 134(1):102-13. PubMed ID: 23784959
[TBL] [Abstract][Full Text] [Related]
31. Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines.
Fenton RG; Turcovski-Corrales SM; Taub DD
J Immunother; 1998 Mar; 21(2):95-108. PubMed ID: 9551360
[TBL] [Abstract][Full Text] [Related]
32. Increased frequencies of CD11b(+) CD33(+) CD14(+) HLA-DR(low) myeloid-derived suppressor cells are an early event in melanoma patients.
Rudolph BM; Loquai C; Gerwe A; Bacher N; Steinbrink K; Grabbe S; Tuettenberg A
Exp Dermatol; 2014 Mar; 23(3):202-4. PubMed ID: 24495013
[TBL] [Abstract][Full Text] [Related]
33. Soluble HLA-G inhibits cell cycle progression in human alloreactive T lymphocytes.
Bahri R; Hirsch F; Josse A; Rouas-Freiss N; Bidere N; Vasquez A; Carosella ED; Charpentier B; Durrbach A
J Immunol; 2006 Feb; 176(3):1331-9. PubMed ID: 16424159
[TBL] [Abstract][Full Text] [Related]
34. Tumors Escape CD4+ T-cell-Mediated Immunosurveillance by Impairing the Ability of Infiltrating Macrophages to Indirectly Present Tumor Antigens.
Tveita AA; Schjesvold F; Haabeth OA; Fauskanger M; Bogen B
Cancer Res; 2015 Aug; 75(16):3268-78. PubMed ID: 26038231
[TBL] [Abstract][Full Text] [Related]
35. Evidence to support the role of HLA-G5 in allograft acceptance through induction of immunosuppressive/ regulatory T cells.
Le Rond S; Azéma C; Krawice-Radanne I; Durrbach A; Guettier C; Carosella ED; Rouas-Freiss N
J Immunol; 2006 Mar; 176(5):3266-76. PubMed ID: 16493088
[TBL] [Abstract][Full Text] [Related]
36. Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation.
Contini P; Ghio M; Poggi A; Filaci G; Indiveri F; Ferrone S; Puppo F
Eur J Immunol; 2003 Jan; 33(1):125-34. PubMed ID: 12594841
[TBL] [Abstract][Full Text] [Related]
37. The Killer Cell Ig-like Receptor 2DL4 Expression in Human Mast Cells and Its Potential Role in Breast Cancer Invasion.
Ueshima C; Kataoka TR; Hirata M; Furuhata A; Suzuki E; Toi M; Tsuruyama T; Okayama Y; Haga H
Cancer Immunol Res; 2015 Aug; 3(8):871-80. PubMed ID: 25735953
[TBL] [Abstract][Full Text] [Related]
38. Defective antigen presentation by human melanoma cell lines cultured from advanced, but not biologically early, disease.
Alexander MA; Bennicelli J; Guerry D
J Immunol; 1989 Jun; 142(11):4070-8. PubMed ID: 2469732
[TBL] [Abstract][Full Text] [Related]
39. T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy.
Tjin EP; Konijnenberg D; Krebbers G; Mallo H; Drijfhout JW; Franken KL; van der Horst CM; Bos JD; Nieweg OE; Kroon BB; Haanen JB; Melief CJ; Vyth-Dreese FA; Luiten RM
Clin Cancer Res; 2011 Sep; 17(17):5736-47. PubMed ID: 21750202
[TBL] [Abstract][Full Text] [Related]
40. HLA-G and HLA-E in patients with juvenile idiopathic arthritis.
Prigione I; Penco F; Martini A; Gattorno M; Pistoia V; Morandi F
Rheumatology (Oxford); 2011 May; 50(5):966-72. PubMed ID: 21186170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
